U.S. Judge Blocks Colorado Panel’s Attempt to Cap Amgen’s Enbrel Price

A federal judge in the United States issued an order that prevents a Colorado state panel from imposing a price cap on Amgen’s blockbuster arthritis drug Enbrel. The ruling effectively blocks the state’s effort to limit the medication’s cost to patients.

The decision is a win for Amgen, allowing the company to continue setting the price of Enbrel without the state‑imposed ceiling. Industry observers note that the outcome may influence how other states approach drug‑price regulation.

The case arrives amid broader discussions about drug affordability, including a new Medicare program that would make obesity treatments available at $50 a month for more Americans. The Enbrel ruling highlights the ongoing tension between state pricing initiatives and pharmaceutical pricing strategies.